LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission
01-02-2021
gowithstock / shutterstock.com
The University of Oxford has partnered with UK pharmaceutical company AstraZeneca to develop and manufacture the university’s trial COVID-19 vaccine.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
